These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 16217281

  • 1. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C, Touloupidis S, Galaktidou G, Kortsaris AH, Boutis A, Mouratidou D.
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH.
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [Abstract] [Full Text] [Related]

  • 4. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M.
    Cancer; 2006 Dec 15; 107(12):2842-9. PubMed ID: 17103443
    [Abstract] [Full Text] [Related]

  • 5. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer.
    Morita T, Kikuchi T, Hashimoto S, Kobayashi Y, Tokue A.
    Eur Urol; 1997 Dec 15; 32(2):237-44. PubMed ID: 9286660
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W, Muley T.
    Anticancer Res; 1999 Dec 15; 19(4A):2669-72. PubMed ID: 10470217
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar 15; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 14. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, Trimbos JB.
    Gynecol Oncol; 2000 Apr 15; 77(1):164-70. PubMed ID: 10739706
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D.
    Cancer; 2002 Jun 01; 94(11):2914-22. PubMed ID: 12115379
    [Abstract] [Full Text] [Related]

  • 16. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma.
    Uenishi T, Yamazaki O, Yamamoto T, Hirohashi K, Tanaka H, Tanaka S, Hai S, Ono K, Kubo S.
    J Hepatobiliary Pancreat Surg; 2006 Jun 01; 13(3):239-44. PubMed ID: 16708302
    [Abstract] [Full Text] [Related]

  • 17. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
    Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M.
    J Urol; 1997 Aug 01; 158(2):338-41. PubMed ID: 9224298
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment delay and prognosis in invasive bladder cancer.
    Liedberg F, Anderson H, Månsson W.
    J Urol; 2005 Nov 01; 174(5):1777-81; discussion 1781. PubMed ID: 16217282
    [Abstract] [Full Text] [Related]

  • 20. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C, Eltze E, Von Struensee D, Wülfing P, Bode ME, Bettendorf O, Piechota H, Hertle L.
    Aktuelle Urol; 2004 Aug 01; 35(4):331-8. PubMed ID: 15459875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.